Pfizer officials presented data Wednesday showing that a third coronavirus shot could boost disease-fighting antibodies many times higher than the level yielded by the standard two-dose regimen. (Angela Weiss/AFP/Getty Images)
While company data showed a slight drop in efficacy against any symptomatic cases of covid-19, from 96 percent protection in the first two months following vaccination to 84 percent after four months, the vaccine was 97 percent effective against severe disease.
The evolving recommendations around face coverings served as a dismal acknowledgment that infections in the United States have quadrupled in July, even as highly effective vaccines are widely available.
The Washington Post is providing our daily live updates, comprehensive guide to the pandemic and our Coronavirus Updates newsletter for free, so that all readers have access to this important information about the coronavirus pandemic.